| Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis FE Mózes, JA Lee, EA Selvaraj, ANA Jayaswal, M Trauner, J Boursier, ... Gut 71 (5), 1006-1019, 2022 | 417 | 2022 |
| Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany C Labenz, Y Huber, E Kalliga, M Nagel, C Ruckes, BK Straub, PR Galle, ... Alimentary pharmacology & therapeutics 48 (10), 1109-1116, 2018 | 128 | 2018 |
| Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation Y Huber, M Boyle, K Hallsworth, D Tiniakos, BK Straub, C Labenz, ... Clinical Gastroenterology and Hepatology 17 (10), 2085-2092. e1, 2019 | 110 | 2019 |
| Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany C Labenz, Y Huber, M Michel, M Nagel, PR Galle, K Kostev, ... Digestive diseases and sciences 65, 2112-2119, 2020 | 105 | 2020 |
| Improvement of non‐invasive markers of NAFLD from an individualised, web‐based exercise program Y Huber, D Pfirrmann, I Gebhardt, C Labenz, N Gehrke, BK Straub, ... Alimentary Pharmacology & Therapeutics 50 (8), 930-939, 2019 | 101 | 2019 |
| Nonalcoholic fatty liver disease increases the risk of anxiety and depression C Labenz, Y Huber, M Michel, M Nagel, PR Galle, K Kostev, ... Hepatology Communications 4 (9), 1293-1301, 2020 | 99 | 2020 |
| Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients C Labenz, JS Baron, G Toenges, JM Schattenberg, M Nagel, MF Sprinzl, ... Alimentary Pharmacology & Therapeutics 48 (3), 313-321, 2018 | 97 | 2018 |
| Health-related quality of life in patients with compensated and decompensated liver cirrhosis C Labenz, G Toenges, JM Schattenberg, M Nagel, Y Huber, JU Marquardt, ... European journal of internal medicine 70, 54-59, 2019 | 69 | 2019 |
| Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease L Kaps, C Labenz, PR Galle, J Weinmann-Menke, K Kostev, ... United European Gastroenterology Journal 8 (8), 942-948, 2020 | 65 | 2020 |
| Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy C Labenz, G Toenges, Y Huber, M Nagel, JU Marquardt, JM Schattenberg, ... Alimentary Pharmacology & Therapeutics 50 (10), 1112-1119, 2019 | 58 | 2019 |
| Adipokines and endotoxemia correlate with hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) A Nier, Y Huber, C Labenz, M Michel, I Bergheim, JM Schattenberg Nutrients 12 (3), 699, 2020 | 52 | 2020 |
| Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy C Labenz, L Beul, G Toenges, JM Schattenberg, M Nagel, MF Sprinzl, ... European journal of internal medicine 60, 96-100, 2019 | 49 | 2019 |
| Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infection C Labenz, WM Kremer, JM Schattenberg, MA Wörns, G Toenges, ... Journal of Investigative Medicine 68 (6), 1199-1202, 2020 | 47 | 2020 |
| Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL C Labenz, A Arslanow, M Nguyen-Tat, M Nagel, MA Wörns, MC Reichert, ... Journal of Hepatology 77 (3), 695-701, 2022 | 46 | 2022 |
| Incident dementia in elderly patients with nonalcoholic fatty liver disease in Germany C Labenz, K Kostev, L Kaps, PR Galle, JM Schattenberg Digestive diseases and sciences 66 (9), 3179-3185, 2021 | 46 | 2021 |
| Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis C Labenz, M Nagel, WM Kremer, M Hilscher, CA Schilling, G Toenges, ... Alimentary pharmacology & therapeutics 52 (3), 527-536, 2020 | 41 | 2020 |
| Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes G Pennisi, M Enea, V Falco, GP Aithal, N Palaniyappan, Y Yilmaz, ... Hepatology 78 (1), 195-211, 2023 | 40 | 2023 |
| Patterns of liver injury in COVID-19–a German case series JM Schattenberg, C Labenz, MA Woerns, P Menge, A Weinmann, ... United European Gastroenterology Journal 8 (7), 814-819, 2020 | 39 | 2020 |
| Tumor incidence in patients with non-alcoholic fatty liver disease Y Huber, C Labenz, M Michel, MA Wörns, PR Galle, K Kostev, ... Deutsches Ärzteblatt International 117 (43), 719, 2020 | 38 | 2020 |
| Cardiovascular risk categories in patients with nonalcoholic fatty liver disease and the role of Low‐Density lipoprotein cholesterol C Labenz, JH Prochaska, Y Huber, M Nagel, BK Straub, P Wild, PR Galle, ... Hepatology Communications 3 (11), 1472-1481, 2019 | 37 | 2019 |
